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Abstract
It is well established that activation of the transcription factor signal transducer and activator of 
transcription 1 (STAT1) is required for the interferon-γ (IFN-γ)–mediated antiviral response. 
Here, we found that IFN-γ receptor stimulation also activated Unc-51-like kinase 1 (ULK1), an 
initiator of Beclin-1-mediated autophagy. Furthermore, the interaction between ULK1 and the 
mitogen-activated protein kinase kinase kinase MLK3 (mixed lineage kinase 3) was necessary for 
MLK3 phosphorylation and downstream activation of the kinase ERK5. This autophagy-
independent activity of ULK1 promoted the transcription of key antiviral IFN-stimulated genes 
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(ISGs) and was essential for IFN-γ–dependent antiviral effects. These findings define a previously 
unknown IFN-γ pathway that appears to be a key element of the antiviral response.
Introduction
Interferons (IFNs) are secreted cytokines that act as the first line of defense against viral 
infections (1). IFN-inducible activation of signal transducer and activator of transcription 1 
(STAT1) and STAT2 is important for an antiviral response associated with type I and type III 
IFNs (2). By contrast, there is little information on the signaling effectors that mediate the 
antiviral effects of the type II IFN, IFNγ(3). IFNγ initiates its biological activities by 
binding to its cognate heterodimeric cell surface receptor, composed of two ligand binding 
IFN-gamma receptor 1 (IFNGR1) subunit chains and two signal-transducing IFNGR2 chains 
(4). This interaction triggers activation of several downstream signaling events, including the 
canonical Janus kinase (JAK)-STAT1 pathway, and non-STAT pathways, such as mitogen-
activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), mechanistic target of 
rapamycin complex 2 (mTORC2), calcium/calmodulin-dependent protein kinase II 
(CaMKII), and nuclear factor kappa-B (NF-kB) cellular pathways (3,5,6,7,8). Although 
IFNγ-mediated activation of STAT1 is required for several IFNγ-dependent antiviral 
responses, some of these activities are STAT1-independent, which implies that there may be 
activation of alternate and complementary pathways by IFNγ stimulation during a viral 
infection (3).
The human serine/threonine kinase ULK1 (Unc-51-like kinase 1) is the human homolog of 
Saccharomyces cerevisiae autophagy-related protein kinase Atg1, which promotes 
autophagy (9). However, ULK1 activity is required for type I IFN-induced activation of p38 
MAPK, and for its antiproliferative effects in normal hematopoiesis and myeloproliferative 
neoplasms (9). In light of these findings, we questioned whether ULK1 could also be 
activated downstream of the type II IFNR, IFNGR, and whether ULK1 is required for IFNγ-
mediated antiviral activity. We found that IFNγ-dependent engagement of ULK1 promoted 
activation of downstream IFNγ-dependent signaling events and transcription of key antiviral 
IFN-stimulated genes (ISGs). We identified that mixed lineage kinase 3 (MLK3) interacted 
with and was phosphorylated by ULK1 after engagement of the IFNGR. This study defines 
the molecular mechanism by which ULK1 activates IFNγ-mediated antiviral responses.
Results
IFNγ treatment promotes ULK1-dependent MLK3 activation
We speculated that IFNγ activation of the IFNGR may engage ULK1, which could in turn 
interact with other cellular signaling effectors. To identify potential IFNγ-dependent binding 
partners of ULK1, we performed nano-liquid chromatography (nLC) and tandem mass 
spectrometry (MS/MS) analysis of endogenous protein-ULK1 complexes 
immunoprecipitated from untreated and IFNγ-treated KT-1 leukemia cells. We found that 
ULK1 interacted with 35 proteins under untreated conditions, 75 proteins under both 
untreated and IFNγ-treated conditions, and 34 unique proteins following IFNγ treatment for 
10 minutes (min) (Fig. 1A). Pathway and process enrichment analysis of the putative ULK1 
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interactors in KT-1 cells identified that 6 known IFNγ signaling pathway-related proteins 
bound to ULK1 after IFNγ stimulation (Fig. 1B, red asterisk and Table S1). Additionally, a 
separate pathway and process enrichment analysis of the 34 putative ULK1 interactors after 
IFNγ treatment revealed enrichment of 20 proteins associated with viral processes (Fig. 1C, 
red asterisk and Table S2) and indicated that MAP kinase kinase kinase 11 (MAP3K11, also 
MLK3) was involved in both IFNγ signaling and virus-associated processes (Table S1 and 
S2). When we probed the binding interaction between ULK1 and MLK3 by co-
immunoprecipitation followed by immunoblotting in IFNγ-sensitive KT-1 and U937 cells, 
we found that ULK1 and MLK3 interacted in both unstimulated and IFNγ-treated cells (Fig. 
2, A and B). Furthermore, in vitro kinase reactions between ULK1 and heat-inactivated 
MLK3 increased the ATP consumption in vitro (Fig. 2C), and loss of Ulk1/2 in mouse 
embryonic fibroblasts (MEFs) inhibited IFNγ-induced phosphorylation of MLK3 within its 
activation loop (10) at Thr277 and Ser281 (Fig. 2D). These data suggest that MLK3 is 
activated downstream of ULK1 during engagement of the IFNGR.
IFNγ-dependent signaling events require ULK1/2 activity
MLK3, a member of the MAP3K family, is a Ser/Thr protein kinase essential for activation 
of several MAPK signaling cascades in response to different stimuli (11,12,13). Specifically, 
in response to IFNγ MLK3 is required for the activation of the transcription factor CCAAT/
enhancer-binding protein-β (C/EBP-β) (14). However, it is not known whether MLK3 
promotes activation of MAP kinases after engagement of the IFNGR. Thus, we evaluated the 
importance of MLK3 for IFNγ-induced phosphorylation of the MAP kinases ERK5, 
ERK1/2 and JNK, using Mlk3+/+ and Mlk3−/− mouse embryonic fibroblasts (MEFs) (12). 
IFNγ-mediated activation of ERK5 by phosphorylation of the Thr-Glu-Tyr motif within the 
activation loop of its kinase domain (15) (Thr218/Tyr220) was defective in Mlk3−/− MEFs 
when compared to Mlk3+/+ MEFs (Fig. 3A). In contrast, IFNγ-induced phosphorylation of 
ERK1/2 and JNK were unaffected in Mlk3−/− cells (Fig. 3, B and C). When we examined 
whether ULK1 is required for IFNγ-dependent phosphorylation of ERK5 kinase in 
Ulk1/2+/+ and Ulk1/2−/− MEFs (16), we found that ERK5 phosphorylation in MEFs is 
defective in the absence of Ulk1/2 (Fig. 4A). However, there was some increased baseline 
phosphorylation of ERK5 in Ulk1/2+/+ MEFs compared to Ulk1/2−/− MEFs (Fig. 4A). 
Furthermore, IFNγ stimulation resulted in phosphorylation of both ERK1/2 and JNK 
kinases, as well as STAT1, independently of Ulk1/2 presence (Fig. 4, B and C and fig. S1). 
Together, our results suggest that ULK1/2 activity is required for IFNγ-mediated 
phosphorylation of MLK3, which in turn is required for IFNγ-induced activation of ERK5.
Once activated, ERK5 plays a critical role as a master regulator of transcription by 
promoting the activation of many transcription factors and protein kinases, including p90 
ribosomal S6 kinase 1 (p90RSK1) (16,17). The p90RSK1 Ser/Thr kinase modulates several 
biological processes by increasing both transcription and mRNA translation of specific 
genes (18,19,20). IFNγ-induced phosphorylation of p90RSK1 was defective in Ulk1/2−/− 
MEFs compared to Ulk1/2+/+ MEFs (Fig. 4D). Together these results suggest that ULK1/2 
may play a role in the regulation of IFNγ-induced activation of ERK5 and p90RSK1.
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ULK1/2 activity is essential for transcription of key IFNγ-inducible antiviral genes
To determine whether ULK1/2 activity was required for IFNγ-dependent gene transcription, 
we performed high-throughput single-end RNA-sequencing of total RNA isolated from 
untreated and IFNγ-treated Ulk1/2+/+ and Ulk1/2−/− MEFs. When we used 
Multidimensional scaling (MDS) on the expression of the top 500 genes in all samples to 
determine how distinct and reproducible the samples were, we found that all four biological 
replicates in each group clustered together (fig. 5A). We identified those genes that were 
differentially expressed after IFNγ treatment using edgeR (21). This analysis revealed that 
the expression of 793 genes was decreased and that of 644 genes was increased in IFNγ-
treated Ulk1/2+/+ MEFs compared to IFNγ-treated Ulk1/2−/− MEFs (Fig. 5B). Moreover, 
IFNγ treatment altered the expression of 338 genes in Ulk1/2+/+ MEFs (Fig. 5C, green 
ellipse, and fig. S2A), and 376 genes in Ulk1/2−/− MEFs (Fig. 5C, blue ellipse, and fig. 
S2B). From these, 268 common genes were differentially expressed in both groups after 
IFN-γ treatment (Fig. 5C, fig. S3, and Table S3). We also identified 70 IFN-γ-stimulated 
genes that were expressed only in Ulk1/2+/+ MEFs (Fig. 5C, fig. S4, and Table S4), and 108 
IFNγ-stimulated genes that were expressed only in Ulk1/2−/− cells (Fig. 5C, fig. S5, and 
Table S5). Gene ontology analyses were performed to classify the differentially expressed 
genes detected following IFNγ treatment in both genotypic groups, those only in Ulk1/2+/+ 
cells, and those only in Ulk1/2−/− cells among ontology clusters (fig. S6A–C and Table S6–
S8). The 268 commonly differentially expressed genes are mainly associated with processes 
involved in the defense response to virus infection, namely the innate immune response and 
antigen processing and presentation (fig. S6A and Table S6). The 70 genes differentially 
expressed only in Ulk1/2+/+ MEFs are predominantly associated with processes involved in 
immune cell differentiation, regulation of the JAK-STAT cascade, and regulation of 
inflammatory responses (fig. S6B and Table S7). By contrast, the 108 genes differentially 
expressed only in Ulk1/2−/− MEFs were predominantly associated with regulation of 
leukocyte proliferation and migration and positive regulation of the MAPK cascade (fig. 
S6C and Table S8). To closely evaluate whether the absence of Ulk1/2 affects IFNγ-
mediated expression of antiviral genes, we selected the IFNγ-inducible genes depicted in 
our gene ontology analysis (Table S6–S8) associated with antiviral processes (total 66 
genes) (22,23). From these genes, we found that expression of 46 genes was increased by 
IFNγ more in Ulk1/2+/+ MEFs than Ulk1/2−/− MEFs (Fig. 5D) and overall this difference 
was statistically significant (Fig. 5E).
To evaluate whether ULK1/2 activity was required for optimal IFNγ-dependent 
transcriptional activation of ISGs, we generated Ulk1/2+/+ and Ulk1/2−/− MEFs stably 
expressing an IFNγ activation site (GAS) element-luciferase reporter gene (GAS-LUC) and 
performed luciferase reporter assays. IFNγ-induced transcriptional activation of GAS 
elements was significantly reduced in Ulk1/2−/− cells compared to Ulk1/2+/+ cells (Fig. 6A). 
Additionally, when we examined the specific role of ULK1/2 on the expression of select 
IFNγ-inducible antiviral genes Cxcl10 (24,25), Oasl2 and Ifit3 (26,27) by qRT-PCR, we 
found that expression of these genes after IFNγ treatment was significantly decreased in the 
absence of Ulk1/2 (Fig. 6, B to D). Although the activation of ULK1 promotes induction of 
autophagy (28), treatment of Ulk1/2+/+ MEFs with the autophagy inhibitor, chloroquine, did 
not significantly affect IFNγ-mediated mRNA expression of Cxcl10, Oasl2 and Ifit3 (fig. 
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S7, A to C). Moreover, siRNA-mediated knockdown of VPS34 (PIK3C3) and Beclin-1 
(BECN1), which are necessary for ULK1-mediated autophagy (29), did not reduce IFNγ-
induced expression of antiviral ISGs in KT-1 cells (fig. S7, D to I). These results suggest that 
the key role of ULK1/2 related to IFNγ-mediated transcription of antiviral genes is 
independent of the activation of autophagy.
To determine whether ULK1 activity was also required for IFNγ-induced transcription of 
select antiviral genes in human cells, we generated KT-1 ULK1 knockout (KO) cells using 
CRISPR (clustered regularly interspaced short palindromic repeats)–Cas9 genomic editing. 
Plasmids encoding Cas9 and single-guide RNA (sgRNA) targeting the ULK1 gene (fig. S8) 
were transduced into KT-1 cells, and stably-transduced cells were selected with blasticidin 
and puromycin antibiotics. The complete absence of ULK1 protein was confirmed using 
western blot analysis and by comparing ULK1 abundance between the KT-1 parental cell 
line (ULK1 wild-type [WT]) and KT-1 ULK1 KO cells (Fig. 6E). We verified that IFNγ-
induced gene expression of the antiviral effectors CXCL10, OAS1, IFIT3, and IRF1 was 
significantly reduced in ULK1 KO cells compared to ULK1 WT cells by qRT-PCR analysis 
(Fig. 6, F to I). Together, our data suggest that ULK1 promotes antiviral-ISG transcription.
ULK1/2 kinase activity is required for IFNγ-induced antiviral responses
Because ULK1/2 expression was required for the optimal transcription of select IFNγ-
induced antiviral genes, we tested whether ULK1 was required for IFNγ-stimulated antiviral 
responses. For this, we compared the protective effects of mouse IFNγ on protection from 
encephalomyocarditis virus (EMCV)-induced cell death in Ulk1/2+/+ and Ulk1/2−/− MEFs. 
We found that cells that lacked Ulk1/2 were less responsive to IFNγ treatment than WT cells 
(Fig. 7A). Moreover, human fibrosarcoma 2fTGH cells were less sensitive to the antiviral 
effects of human IFNγ treatment against EMCV infection when treated with the ULK1 
kinase inhibitor MRT68921 (30) (Fig. 7B). Similarly, selective inhibition of ERK5 activity 
with XMD8–92 (31) resulted in a reduction of IFNγ-induced expression of the antiviral 
genes Cxcl10 and Ifit3 in Ulk1/2+/+ MEFs (Fig. 7C) and of IFNγ-induced antiviral effects in 
human 2fTGH cells (Fig. 7D). Together, these data suggest that engagement of the ULK1/2-
ERK5 pathway augments IFNγ-dependent antiviral responses (Fig. 7E).
Discussion
IFNγ is a critical immunomodulator, regulating the innate and adaptive immune responses 
to pathogen infection (32). Indeed, both IFNγ KO and IFNGR KO mice are more 
susceptible to bacterial and viral infections than their WT counterparts (33,34,35,36). 
Moreover, mice injected with a monoclonal antibody against IFNγ succumb to Toxoplasma 
gondii infection (37) and Listeria monocytogenes at higher rates (38). Distinct from the 
ability of IFNγ to influence the differentiation and activation of specific immune cell subsets 
required for pathogen clearance, IFNγ promotes apoptosis of pathogen-infected cells and 
induces the expression of type I IFNs and of several antiviral and antimicrobial genes 
(39,40). However, a comprehensive understanding of the signaling pathways activated 
downstream of the IFNGR and how these impact IFNγ-driven responses remains unclear. 
Herein we provide evidence that IFNγ-induced engagement of ULK1 was required to inhibit 
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virus infection. We found that lack of Ulk1/2 genes or pharmacological inhibition of the 
ULK1/2 kinase activity abrogated IFNγ-induced antiviral activity. This correlated with 
defective IFNγ-mediated transcription of antiviral genes in the absence of ULK1/2 activity, 
although we cannot exclude that additional pathways may participate in the induction of 
antiviral responses. Our work suggests that IFNγ-signaling involves the interaction of ULK1 
with MLK3, which was required for IFNγ-dependent phosphorylation/activation of MLK3. 
These data suggest that ULK1 likely acts upstream, either as a kinase or a scaffold protein, 
of IFNγ-activated MAPK signaling cascades. In human fibroblasts, MLK3 is required for 
both cytokine- and mitogen-induced activation of several MAPK signaling cascades 
(ERK1/2, JNK, and p38 MAPK) (41). Moreover, tumor necrosis factor (TNF)-induced 
stimulation of JNK, but not p38 MAPK or ERK1/2, is defective in Mlk3−/− MEFs when 
compared to WT cells (12). Similarly, MLK3 is required for IFNγ-driven gene expression, 
independently of ERK1/2 activation (15). Here we showed in MEFs that both Ulk1/2 and 
Mlk3 were required for IFNγ-mediated phosphorylation of ERK5, but not JNK and 
ERK1/2. These data suggest that ULK1 and MLK3 may act upstream of MEKK2, MEKK3 
or MEK5 kinases, which are known to activate ERK5 in IFNγ-stimulated cells (42). Our 
results support a model in which IFNγ-dependent engagement of ULK1 leads to 
phosphorylation of MLK3 and ERK5, which promotes transcription of antiviral ISGs and 
consequent IFNγ-induced antiviral responses that may complement the antiviral effects 
induced by the canonical JAK1/JAK2-STAT signaling.
Autophagy is a degradative process that aids the host immune response against viral 
infections, including induction of type I IFN production and activation of IFNγ-induced 
JAK-STAT signaling (43,44). Assembly of the nondegradative Atg5-Atg12/Atg16L1 
autophagy protein complex is also required for IFNγ-dependent antiviral activity (45). In 
contrast, ULK1-dependent autophagy activates a different pathway of phagophore 
nucleation that requires phosphorylation of Beclin-1 and activation of vacuolar protein 
sorting 34 (VPS34) (46). Using pharmacologic and genetic inhibition we found that 
autophagy is not required for the effects of ULK1 on IFNγ-dependent gene expression. 
Thus, multicellular organisms may have developed ways to use autophagy-related proteins 
for additional immune functions. In support of this, here we report a nondegradative role of 
ULK1 that is required for transcription of IFNγ inducible antiviral genes.
The precise mechanisms by which ULK1 or MLK3 may stimulate ERK5 phosphorylation 
remain undetermined. MEK5 is the direct upstream activator of ERK5 (47), and MEKK2/3 
(48,49,50), Cot/TPL-2 (51) and MLTK (52) are MAP3Ks that activate ERK5 in response to 
multiple stimuli. Additionally, another MAP3K, transforming growth factor β-activated 
kinase 1 (TAK1), interacts with MEKK3 and promotes its autophosphorylation in TFNα-
signaling (53). Similarly, ULK1 and/or MLK3 could act as scaffold proteins, or MAP3Ks of 
ERK5 upstream kinases after IFNγ treatment. Although p38 MAPK activity is not required 
for IFNγ-induced transcription of ISGs in MEFs (54), it is involved in the generation of 
IFNγ-inducible biological effects in different human cell types (55,56,57,58). Given that 
ULK1 promotes p38 MAPK activity downstream of the type I IFNR (9), in future studies, it 
would be of interest to evaluate whether ULK1-MLK3 interactions are required for IFNγ-
dependent activation of p38 MAPK in human cells. Viewed altogether our studies identify 
an IFN-γ−stimulated signaling cascade that is critical for expression of IFNγ-inducible 
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ISGs and antiviral responses. These findings may suggest new points of therapeutic 
intervention for the treatment of several diseases where IFNγ has proven clinical activity 
(59,60,61) or how to enhance immune checkpoint blockade where IFNγ responses are 
involved (62,63).
Materials and Methods
Cell culture
KT-1 (64) and U937 (CRL-1593.2; ATCC) cells were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (FBS) and antibiotics. 2fTGH cells (65) were 
kindly provided by Dr. George R. Stark (Cleveland Clinic) and were cultured in DMEM 
high glucose medium supplemented with 10% FBS and antibiotics. The immortalized 
Ulk1/2+/+ and Ulk1/2−/− MEFs (17) were kindly provided by Dr. Craig B. Thompson 
(Memorial Sloan-Kettering Cancer Center) and were cultured in DMEM supplemented with 
10% FBS and antibiotics. Primary Mlk3+/+ and Mlk3−/− MEFs were described previously 
(12) and were cultured in DMEM high glucose medium supplemented with 10% bovine 
growth serum, 1x L-glutamine, 1x penicillin/streptomycin solution and 8 μl of 2-
mercaptoethanol per liter of medium. All experiments were performed using primary MEFs 
between passages 2 and 4. The other cell lines were frozen at low passage in liquid nitrogen 
and were kept in culture for no longer than 8 passages. All cells were cultured at 37°C and 
5% CO2. All cells were tested for mycoplasma contamination using MycoAlert PLUS 
mycoplasma detection kit following the manufacturer’s instructions (Lonza).
Reagents
IFNγ recombinant human (# PHC4033) and mouse (# PMC4033) proteins were from Gibco 
(Life Technologies). MRT68921 dual autophagy kinase ULK1/2 inhibitor was purchased 
from Selleckchem (# S7949). Chloroquine (CQ) was purchased from Sigma-Aldrich. 
XMD8–92 was purchased from Tocris (# 4132). The Edit-R human lentiviral ULK1 
sgRNAs (# VSGH10142–246477203) and Edit-R Lentiviral hEF1α-Blast-Cas9 nuclease 
plasmid DNA (# CAS10138) were purchased from GE Healthcare Dharmacon. ON-
TARGETplus Non-targeting Control Pool siRNA (# D-001810–10-05), ON-TARGETplus 
PIK3C3 siRNA (SMARTpool: # L-005250–00-0005) and ON-TARGETplus BECN1 siRNA 
(SMARTpool: # L-010552–00-0005) were purchased from Dharmacon. Antibodies against 
ULK1 (D8H5) (#8054), MLK3 (#2817), phospho-ERK5 (Thr218/Tyr220) (#3371), ERK5 
(D3I5V) (#12950), phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (D13.14.4E) (#4370), 
p44/42 MAPK (ERK1/2) (#9102), phospho-SAPK/JNK (Thr183/Tyr185) (81E11) (#4668), 
SAPK/JNK (#9252), phospho-STAT1 (Ser727) (D3B7) (#8826), phospho-STAT1 (Tyr701) 
(D4A7) (#7649), phospho-p90RSK (Thr359/Ser363) antibody (#9344), and RSK1 (D6D5) 
(#8408) were purchased from Cell Signaling. Anti-MLK3 (phospho Thr277 + Ser281) 
antibody (#ab191530) was purchased from abcam and STAT1 p84/p91 antibody (E-23) 
(#sc-346) was from Santa Cruz Biotechnology. Antibody against GAPDH (6C5) 
(#MAB374) was purchased from EMD Millipore.
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Mass spectroscopy analyses
To identify proteins that interact with endogenous ULK1, KT-1 cells were left untreated or 
were treated with 5×103 IU/ml of human IFNγ for 10 min and then lysed in NP-40 buffer 
(20mM HEPES pH7.4, 180mM KCl, 0.2mM EGTA, 0.1% NP-40) supplemented with 
protease and phosphatase inhibitors. Three mg of protein (total cell lysates) from untreated 
and IFNγ-treated samples were used for immunoprecipitation (IP) of endogenous protein-
ULK1 complexes using ULK1 (D8H5) rabbit monoclonal antibody-conjugated to magnetic 
beads (Custom order, Cell signaling). As control, the same procedure was followed for 
IFNγ-treated lysates, but using Rabbit (DA1E) monoclonal antibody IgG XP Isotype 
control-conjugated to magnetic beads (#8726, Cell Signaling) instead of the ULK1 antibody. 
After incubating the samples overnight with rotation at 4°C, the beads were washed two 
times with NP-40 buffer and one time with washing buffer (20mM HEPES pH7.4, 180mM 
KCl, 0.2mM EGTA). Protein-ULK1 complexes were eluted from the beads by incubation 
with lane marker reducing sample buffer (Pierce) at 95°C for 10 min and proteomic analyses 
were performed in the Northwestern Proteomics Core Facility (Northwestern University, 
Chicago). IP-eluted proteins were initially separated using SDS-PAGE and cut into ten 
equivalent height bands prior to standard in-gel digestion (66). Resulting peptides were 
extracted from the gel pieces and desalted using solid phase extraction on a Pierce C18 Spin 
column, prior to elution in 40 μL of 80% acetonitrile in 0.2% formic acid. After 
lyophilization, peptides were reconstituted with 0.1% formic acid in water and injected onto 
a trap column (150 μm ID × 3 cm) coupled with a nanobore analytical column (75 μm ID × 
15 cm, both ReproSil C18aq, 3 μm). Samples were separated using a linear gradient of 
solvent A (95% water, 5% acetonitrile, 0.1% formic acid) and solvent B (5% water, 95% 
acetonitrile, 0.1% formic acid) over 60 min. nLC-MS/MS data were obtained on a Velos 
Orbitrap (Thermo) mass spectrometer. Data were searched using Mascot (Matrix Science) 
2.5 against the human SwissProt database and results were reported at 1% FDR in Scaffold 
4.5 (Proteome Software). Proteins identified by nLC-MS/MS analysis in the control group 
(Rabbit IgG) were excluded from our data analysis.
Protein function enrichment analysis
Protein lists identified in untreated and/or IFNγ-treated groups were converted to gene lists 
that were submitted to the Metascape database (67,68), a gene annotation and analysis 
resource (http://metascape.org/), for pathway and process enrichment analysis. For each 
given gene list, Metascape carries pathway and process enrichment analysis using the 
following ontology sources: GO Biological Processes, KEGG Pathway and Reactome Gene 
Sets. All genes in the genome were used as the enrichment background. Terms with p-value 
< 0.01, minimum count 3, and enrichment factor > 1.5 are collected and grouped into 
clusters based on their membership similarities. More specifically, p-values are calculated 
based on accumulative hypergeometric distribution, q-values are calculated using the 
Banjamini-Hochberg procedure to account for multiple testing. Kappa scores were used as 
the similarity metric when performing hierarchical clustering on the enriched terms and then 
sub-trees with similarity > 0.3 are considered a cluster. The most statistically significant 
term within a cluster is chosen as the one representing the cluster.
Saleiro et al. Page 8
Sci Signal. Author manuscript; available in PMC 2019 November 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Co-immunoprecipitation of protein-ULK1 complexes
To confirm the physical interaction between ULK1 and MLK3 identified by nLC-MS/MS 
analysis, KT-1 cells were left untreated or were treated with human IFNγ (5×103 IU/ml) for 
10 min and U937 cells were cultured overnight in serum-free RPMI 1640 medium and then 
were left untreated or were treated with human IFNγ (5×103 IU/ml) for 10 min. After 
treatment, cell pellets were lysed in NP-40 buffer (20mM HEPES pH7.4, 180mM KCl, 
0.2mM EGTA, 10% glycerol, 0.1% NP-40) supplemented with protease and phosphatase 
inhibitors. For immunoprecipitation of endogenous protein-ULK1 complexes, 200 μg of 
protein (total cell lysates) from each sample were incubated overnight at 4°C with rotation 
with ULK1 (D8H5) rabbit monoclonal antibody (1:100) (#8054, Cell signaling), followed 
by incubation for 1 hour at 4°C with rotation with protein G Sepharose 4 Fast Flow beads 
(GE Healthcare Life Sciences). As control, the same procedure was followed using Rabbit 
(DA1E) monoclonal antibody IgG XP Isotype control (#3900, Cell Signaling) instead of 
ULK1 antibody. After immunoprecipitation, the beads were washed three times with NP-40 
buffer without glycerol. Protein-ULK1 complexes were eluted from the beads by incubation 
with lane marker reducing sample buffer (Pierce) at 95°C for 10 min. Eluates were resolved 
by SDS-PAGE and processed for immunoblotting analyses.
In vitro kinase assay
Recombinant human MLK3 active protein (#M19–11G, SignalChem) was heat inactivated 
at 65°C for 20 min in a sonicating bath. To confirm heat inactivation of MLK3 recombinant 
protein, kinase reactions between MLK3 heat inactive protein (1 μg) and MBP substrate (5 
μg) (#M42–51N, SignalChem) were performed. To determine whether ULK1 can directly 
phosphorylate MLK3, kinase reactions between recombinant human ULK1 active protein 
(100 ng) (#U01–11G, SignalChem) and MLK3 heat inactive protein (1.66 μg) were 
performed. As controls, the same kinase reactions were carried out, but using each 
recombinant protein alone. For each kinase reaction we used DTT (#D86–09B, 
SignalChem), ATP (#V915A, Promega), and 5x kinase buffer (#K03–09, SignalChem) 
following the manufacturer’s instructions. Kinase mixtures were incubated for 40 min 
shaking at 300 rpm and 30°C. The ADP formed from the kinase reactions was measured 
using the ADP-Glo Kinase Assay Kit (#V6930, Promega) following the manufacturer’s 
instructions.
MEFs treatment and lysis for immunoblotting analyses
Prior to IFNγ treatment, MEFs were either cultured in 10% FBS-containing medium (for 
detection of phosphorylation of ERK5, STAT1 and ERK1/2) or starved overnight (for 
detection of phosphorylation of JNK, MLK3, and p90RSK1). MEFs were then treated with 
5×103 IU/ml of mouse IFNγ for 10 or 30 min, as indicated. After treatment, cell pellets 
were lysed with lysis buffer (50 mM HEPES pH 7.3, 150 mM NaCl, 1.5 mM MgCl2, 1 mM 
EDTA pH 8.0, 100 μM sodium fluoride, 10 μM sodium pyrophosphate, 0.5% Triton X-100, 
and 10% glycerol) supplemented with protease and phosphatase inhibitors.
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Immunoblotting analyses
Equal amounts of total cell lysates were resolved by SDS-PAGE and transferred to a 
Immobilon-P PVDF membrane (Millipore) using the Trans-Blot Turbo transfer system (Bio-
Rad). For immunoblotting analyses, the membranes were probed with primary antibodies, 
followed by horseradish peroxidase (HRP)-conjugated secondary antibodies, and antibody 
binding was detected by enhanced chemiluminescence using Amersham ECL prime western 
blotting detection reagent (GE Healthcare Life Sciences). Bands corresponding to protein of 
interest were scanned and quantified by densitometry using ImageJ software.
Library Construction and RNA-Sequencing (RNA-Seq)
Ulk1/2+/+ and Ulk1/2−/− MEFs were plated as four biological replicates and were either left 
untreated or were treated for 6 hours with 2.5×103 IU/ml of mouse IFNγ. Total RNA was 
isolated using the RNeasy Mini Kit (QIAGEN), following the manufacturer’s instructions. 
Library construction and stranded mRNA sequencing were conducted at the NUSeq Core 
Facility of Northwestern University. Briefly, RNA quality and quantity were first determined 
with the Agilent Bioanalyzer 2100 and Qubit fluorometer, and all samples presented a RNA 
integrity number of 10. Sequencing libraries were prepared from 1μg of high-quality RNA 
samples using Illumina TruSeq Stranded mRNA Library Preparation Kit (Illumina) as per 
the manufacturer’s instructions. This procedure includes mRNA purification and 
fragmentation, cDNA synthesis, 3’ end adenylation, Illumina adapter ligation, library PCR 
amplification and validation. An Illumina NextSeq 500 Sequencer was used to sequence the 
libraries with the production of single-end, 75 bp reads.
RNA-Seq reads mapping and transcript abundance estimation
Raw reads in the fastq format were controlled for quality using Trimmomatic (69). Trimmed 
reads were then aligned to the mouse genome (UCSC mm9) using TopHat v2.1.0 (70). Only 
uniquely mapped reads with a maximum of two mismatches over the whole length of the 
gene were considered for ensuing analyses. Gene annotations came from Ensembl release 
75. Exonic reads were assigned to specific genes from Ensembl release 75 using the htseq-
count script from HTSeq-0.6.1 (71).
Differential analysis of gene regulation at transcript resolution
Gene counts computed by HTSeq were used as input for edgeR (version 3.18.1) (72), which 
was used to calculate the differential expression and analyze the significances of observed 
changes between two groups using the standard edgeR workflow. Genes with Benjamini-
Hochburg adjusted p-values less than 0.01 were considered to be differentially expressed 
unless otherwise specified.
Gene clustering
RNA-Seq results are shown as a heatmap and include transcripts whose expression were the 
most significantly altered by IFNγ treatment in Ulk1/2+/+ and Ulk1/2−/− MEFs. Colored 
rectangles represent normalized total reads per million (RPM) mRNA abundance of the 
transcript. Hierarchical clustering was performed with R version 3.4.0 software using the 
heatmap.2 function and distance correlation. The intensity of the color is proportional to the 
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RPM values from each RNA-Seq measurement, as indicated on the bar next to the heatmap 
image.
Gene Set Enrichment analyses
The gene list of the differentially induced genes by IFNγ found only in Ulk1/2+/+ MEFs was 
submitted to the Metascape database (68,69) (http://metascape.org). Metascape carries 
pathway and process enrichment analysis using the following ontology sources: GO 
Biological Processes, KEGG Pathway and Reactome Gene Sets. Gene ontology functional 
analysis was conducted using default parameters.
Generation of Ulk1/2+/+ and Ulk1/2−/− cell lines stably expressing GAS luciferase reporter 
gene elements
pGF1-GAS-LUC, which expresses a puromycin selection cassette and firefly luciferase 
reporter under the control of a minimal CMV promoter followed by four tandem consensus 
GAS elements (5′-AGTTTTCATATTACTCTAAATC-3′) was purchased from System 
Biosciences (SBI). Reporter vector carrying viral particles was produced by co-transfection 
of the lentiviral plasmid and the packaging vectors into Lenti-X 293T cell line (Clontech). 
Ulk1/2+/+ and Ulk1/2−/− MEFs were infected with virus-containing fresh supernatant using 
Transdux reagent (SBI). Stably-transduced cells were selected using 2 μg/ml of puromycin 
(Gibco, Life Technologies).
Luciferase assays
Ulk1/2+/+ and Ulk1/2−/− MEFs stably expressing pGF1-GAS-LUC were plated in a 96-well 
plate (three or five replicates of 5000 cells per well) and 24 hours later were maintained in 
serum-free RPMI 1640 medium overnight. Serum-starved cells were left untreated (control) 
or were treated with 2.5×103 IU/ml of mouse IFNγ for 6 hours and then lysed using 1x 
Reporter Lysis Buffer (Promega). Luciferase assay substrate buffer (Luciferase Assay 
System # E4030, Promega) was used per the manufacturer’s instructions and luciferase 
activities were measured using a Cytation 3 cell imaging multi-mode microplate reader 
(BioTek).
Quantitative RT-PCR (qRT-PCR) analyses
To determine the effect of ULK1/2 on IFNγ-induced expression of antiviral ISGs, Ulk1/2+/+ 
and Ulk1/2−/− MEFs or KT-1 WT and KT-1 ULK1 KO cells were left untreated or were 
treated for 6 hours with 2.5×103 IU/ml of mouse or human IFNγ, respectively. To determine 
whether ERK5 is required for IFNγ-induced expression of antiviral ISGs, Ulk1/2+/+ MEFs 
were pre-incubated for 1 hour with 0.5μM of the ERK5 inhibitor XMD8–92 followed by 6 
hours of co-treatment with 2.5×103 IU/ml of mouse IFNγ. Cells were treated with vehicle-
control (DMSO) or each compound alone (controls). To define whether inhibition of 
autophagy would affect antiviral ISG expression, KT-1 cells were transfected with control, 
PIK3C3 (VPS34) or BECN1 (Beclin-1) siRNAs using Amaxa Cell Line Nucleofector Kit V 
(Lonza) following the manufacturer’s instructions and, 18 hours later, cells were either left 
untreated or were treated with 2.5×103 IU/ml of human IFNγ for 6 hours. Additionally, 
Ulk1/2+/+ MEFs were pre-incubated for 1 hour with 6μM of chloroquine (CQ) followed by 
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six hours of co-treatment with 2.5×103 IU/ml of mouse IFNγ. As controls, cells were left 
untreated or were treated with each compound alone. Total RNA was isolated using the 
RNeasy Mini Kit (QIAGEN) following the manufacturer’s instructions. 2μg of total cellular 
mRNA was reverse-transcribed into cDNA using the Omniscript RT kit (QIAGEN) and 
oligo(dT)12–18 primers (Life Technologies). Quantitative RT-PCR was carried out using an 
ABI7500 sequence detection system (Applied Biosystems) or a Bio-Rad CFX96 Real Time 
System (Bio-Rad) using commercially-available FAM-labeled primer/probe sets (Thermo 
Fisher) to determine mouse Cxcl10 (Mm00445235_m1), Ifit3 (Mm01704846_s1), Oasl2 
(Mm00496187_m1), and human CXCL10 (Hs01124252_g1), OAS1 (Hs00973635_m1), 
IFIT3 (Hs01922752_s1), IRF1 (Hs00971965_m1), PIK3C3 (Hs00176908_m1), and BECN1 
(Hs01007018_m1) mRNA expression. Mouse Gapdh (Mm99999915_g1) and human 
GAPDH (Hs02758991_g1) were used for normalization. The mRNA amplification was 
calculated as previously (9), and the data were plotted as the increase of fold change as 
compared with control samples.
CRISPR/Cas9 approach to generate ULK1 knockout KT-1 cells
KT-1 cells were transduced with Edit-R Lentiviral hEF1α-Blast-Cas9 Nuclease Plasmid 
DNA and Edit-R Human Lentiviral ULK1 sgRNA (#CAS10138 and #VSGH10142–
246477203, GE Healthcare Dharmacon). Transduction was carried out by spinoculation 
(750g) for 90 min at RT in the presence of Transdux reagent (SBI) followed by 48 hours of 
incubation. Stably-transduced cells were selected using blasticidin (5 μg/ml) and puromycin 
(2.5 μg/ml) antibiotics. One week later, antibiotic-resistant cells were separated from dead 
cells using a BD FACSAria 5-Laser Cell Sorter (BD Biosciences) and performed at the 
Northwestern University Flow Cytometry Core Facility. Lack of ULK1 protein in KT-1 
ULK1 KO cells was confirmed using western blot analysis.
Antiviral assays
Ulk1/2+/+ and Ulk1/2−/− MEFs were seeded in quadruplicate in 96-well plates overnight and 
then treated with the indicated doses of mouse IFNγ for 16 hours. Cells were subsequently 
challenged with EMCV and EMCV-induced cytopathic effects (CPEs) were determined 24 
hours later. Briefly, medium was aspirated and cells were fixed in 95% ethanol for 30 
minutes, then stained with 0.1% crystal violet in 2% ethanol for a further 30 minutes. Cells 
were then destained in 0.5M NaCl in 50% ethanol for 1 hour, then absorbance readings at 
570nm were taken to determine the extent of uninfected, viable cells. For those assays where 
the ULK1 pharmacological inhibitor MRT68921 or the ERK5 inhibitor XMD8–92 were 
included, human fibrosarcoma 2fTGH cells were seeded in quadruplicate in 96-well plates 
and then treated with either human IFNγ for 16 hours or pretreated for 2 hours with 
MRT68921 (1 μM) or with XMD8–92 (5 μM), then the medium removed and the cells 
treated with MRT68921 or XMD8–92 and human IFNγ, as indicated, for a further 16 hours. 
Cells were subsequently challenged with EMCV and EMCV-induced CPEs were determined 
24 hours later, as described above.
Statistical Analyses
PRISM v6.0 software (GraphPad Software) and SAS 9.4. software (SAS Institute Inc.) were 
used for statistical analyses. Unpaired two-tailed t test with Welch’s correction was used for 
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comparison of means between two groups, one-way analysis of variance (ANOVA) was used 
to compare means among more than two independent groups followed by Tukey’s multiple 
comparisons test, and two-way ANOVA with Bonferroni-corrected post-hoc t-tests were 
used to compare the mean differences among groups classified by two factors. Differences 
were considered statistically significant when p values were less than 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Putative binding partners of ULK1 after engagement of the IFNGR.
(A to C) Tandem mass spec analysis of protein-ULK1 complexes from untreated (UT) or 
IFNγ-treated KT-1 cells. Venn diagram (A) indicates the number of proteins that interact 
with endogenous ULK1 in UT (blue), both (black), and after 10 min’ IFNγ-treatment (red) 
conditions. Heatmap analysis (B) is of the putative binding partners of ULK1 identified in 
untreated (UT), IFNγ-treated (IFNγ), and both groups (also Table S1). Ontology analysis 
(C) is of putative ULK1 interactors identified only after IFNγ stimulation (also Table S2). 
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Note: Red rectangles and asterisks highlight (B) IFNγ signaling pathway and (C) viral 
process terms. Data are from of one experiment.
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Fig. 2. ULK1 interacts with and phosphorylates MLK3 during engagement of the IFNGR.
(A and B) Co-immunoprecipitation analysis of ULK1 interaction with MLK3 in KT-1 (A) or 
U937 (B) cells left untreated, or treated with IFNγ for 10 min, as indicated. Blots are 
representative of 3 independent experiments. (C) ADP-Glo kinase assay analysis of ADP 
concentration produced by in vitro kinase reaction of recombinant human ULK1 and heat-
inactivated MLK3 alone, or in combination. Data are means ± SEM of 3 independent 
experiments performed in triplicates. (D) Western blot analysis of pMLK3 in lysates from 
Ulk1/2+/+ and Ulk1/2−/− MEFs treated with IFNγ for 10 or 30 min, as indicated. Blots (top) 
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are representative of 5 independent experiments. Quantified data (bottom) are means ± SEM 
pooled from all experiments. *P<0.05, **P<0.01, ***P< 0.001, and NS; not significant by 
one-way ANOVA followed by Tukey’s multiple comparisons test (C) or two-way ANOVA 
using Bonferroni correction (D).
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Fig. 3. IFNγ stimulates MLK3-mediated activation of ERK5, but not ERK1/2 and JNK.
(A to C) Western blot analysis of pERK5 (A), pERK1/2 (B), and pJNK (C) in lysates from 
Mlk3+/+ and Mlk3−/− MEFs treated with IFNγ for 10 or 30 min, as indicated. Blots (left) are 
representative of 3 (C) or 4 (A,B) independent experiments. Quantified data (right) are 
means ± SEM pooled from all experiments. *P<0.05, ***P< 0.001, and NS; not significant 
by two-way ANOVA using Bonferroni’s correction.
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Fig. 4. ULK1/2 promotes IFNγ-induced phosphorylation of ERK5 and p90RSK1.
(A to D) Western blot analysis of pERK5 (A), pERK1/2 (B), pJNK (C), and p-p90RSK1 (D) 
in lysates from Ulk1/2+/+ and Ulk1/2−/− MEFs treated with IFNγ for 10 or 30 min, as 
indicated. Blots (left) are representative of 3 independent experiments. Quantified data 
(right) are means ± SEM pooled from all experiments. *P<0.05, **P< 0.01, ***P< 0.001, 
and NS; not significant by two-way ANOVA using Bonferroni’s correction.
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Fig. 5. Ulk1/2 augments IFNγ-mediated transcription of ISGs.
(A to E) RNASeq analysis of transcript expression in Ulk1/2+/+ and Ulk1/2−/− MEFs 
untreated or treated with mouse IFNγ for 6 hours, as indicated. Multidimensional (MDS) 
plot of all groups (A) and Volcano plot of differentially expressed genes after IFNγ 
treatment in Ulk1/2+/+ versus Ulk1/2−/− MEFs (B). Venn diagram (C) indicates the gene 
expression overlap existing between differentially expressed genes after IFNγ treatment in 
Ulk1/2+/+ (green ellipse) and Ulk1/2−/− (blue ellipse) MEFs. Heatmap analysis (D) of 
antiviral genes induced in Ulk1/2+/+ MEFs compared to Ulk1/2−/− MEFs by IFNγ 
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treatment. Box plot (E) of log2FC distribution of IFNγ-inducible antiviral genes in 
Ulk1/2+/+ and Ulk1/2−/− MEFs. Data are from 4 biological replicates per group (see also fig. 
S2–S6, and Table S3–S8). Statistical analyses were performed using Wilcoxon unpaired 
rank sum test.
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Fig. 6. ULK1/2 is required for IFNγ-dependent transcriptional induction of antiviral ISGs.
(A) Luciferase reporter assay analysis of GAS promoter activity in Ulk1/2+/+ and Ulk1/2−/− 
cells untreated or treated with IFNγ for 6 hours. Data are means ± SEM from 4 independent 
experiments. (B to D) qRT-PCR analysis of Cxcl10 (B), Oasl2 (C), and Ifit3 (D) mRNA 
expression in Ulk1/2+/+ and Ulk1/2−/−MEFs untreated or treated with IFNγ for 6 hours. 
Data are means ± SEM from 3 (B) or 4 (C and D) independent experiments. (E) Western 
blot analysis of ULK1 in lysate from KT-1 ULK1 KO cells generated by CRISPR/Cas9 
genome editing. Blots are representative of 3 independent experiments. (F to I) qRT-PCR 
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analysis of CXCL10 (F), OAS1 (G), IFIT3 (H), and IRF1 (I) mRNA expression in KT-1 
ULK1 WT and KT-1 ULK1 KO cells were incubated in the presence or absence of IFNγ for 
6 hours. Data are means ± SEM from 3 (F) or 4 (G to I) independent experiments. *P< 0.05, 
**P< 0.01, ***P< 0.001 by Unpaired t test (two-tailed) with Welch’s correction.
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Fig. 7. Requirement of ULK1/2 for the generation of IFNγ-dependent antiviral effects.
(A) Crystal violet viability analysis of EMCV-induced cytopathic effects in Ulk1/2+/+ and 
Ulk1/2−/− MEFs pretreated with IFNγ at the indicated doses for 16 hours and subsequently 
challenged with encephalomyocarditis virus (EMCV) for 24 hours. Data are means ± SEM 
of quadruplicate assays from 3 independent experiments. (B) Crystal violet viability analysis 
of EMCV-induced cytopathic effects in human fibrosarcoma 2fTGH cells pretreated for 2 
hours with the ULK1 kinase inhibitor MRT68921 (MRT) as indicated, then exposed to IFNγ 
for 16 hours before challenge with EMCV for 24 hours. Data are means ± SEM of 
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quadruplicate assays from 3 independent experiments. (C) qRT-PCR analysis of Cxcl10 
(left) and Ifit3 (right) mRNA expression in Ulk1/2+/+ MEFs were treated with DMSO 
(vehicle-control, C), XMD8–92 (XMD), and/or IFNγ, as indicated. Data are means ± SEM 
from 4 independent experiments. (D) Crystal violet viability analysis of EMCV-induced 
cytopathic effects in human fibrosarcoma 2fTGH cells pretreated for 2 hours with the ERK5 
inhibitor XMD8–92 (XMD) as indicated, then exposed to IFNγ for 16 hours before 
challenge with EMCV for 24 hours. Data are means ± SEM of quadruplicate assays from 3 
independent experiments. (E) Schematic illustration of the potential role of ULK1/2 in IFNγ 
signaling. *P<0.05, **P< 0.01, ****P< 0.0001 by one-way ANOVA analysis followed by 
Tukey’s multiple comparisons test (C) or two-way ANOVA with Post-hoc t-tests (A, B and 
D).
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